MX2017003999A - Derivados de acido boronico. - Google Patents
Derivados de acido boronico.Info
- Publication number
- MX2017003999A MX2017003999A MX2017003999A MX2017003999A MX2017003999A MX 2017003999 A MX2017003999 A MX 2017003999A MX 2017003999 A MX2017003999 A MX 2017003999A MX 2017003999 A MX2017003999 A MX 2017003999A MX 2017003999 A MX2017003999 A MX 2017003999A
- Authority
- MX
- Mexico
- Prior art keywords
- acid derivatives
- boronic acid
- lmp7
- inhibitors
- compounds
- Prior art date
Links
- 150000001642 boronic acid derivatives Chemical class 0.000 title 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 abstract 1
- 101001136986 Homo sapiens Proteasome subunit beta type-8 Proteins 0.000 abstract 1
- 102100035760 Proteasome subunit beta type-8 Human genes 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se describen los compuestos de la fórmula (I) son inhibidores de LMP7 y se pueden emplear, inter alia, para el tratamiento de un trastorno autoinmune o neoplasias hematológicas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14003389 | 2014-10-01 | ||
| PCT/EP2015/001973 WO2016050358A1 (en) | 2014-10-01 | 2015-10-01 | Boronic acid derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017003999A true MX2017003999A (es) | 2018-02-09 |
| MX372823B MX372823B (es) | 2020-07-03 |
Family
ID=51751859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017003999A MX372823B (es) | 2014-10-01 | 2015-10-01 | Derivados de ácido borónico. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US10669289B2 (es) |
| EP (1) | EP3201206B1 (es) |
| JP (1) | JP6662865B2 (es) |
| KR (1) | KR102457840B1 (es) |
| CN (1) | CN107001391B (es) |
| AU (1) | AU2015327345B9 (es) |
| BR (1) | BR112017006622A2 (es) |
| CA (1) | CA2963203A1 (es) |
| CL (1) | CL2017000792A1 (es) |
| DK (1) | DK3201206T3 (es) |
| ES (1) | ES2761774T3 (es) |
| IL (1) | IL251302B (es) |
| MX (1) | MX372823B (es) |
| MY (1) | MY186911A (es) |
| NZ (1) | NZ730981A (es) |
| PH (1) | PH12017500293A1 (es) |
| RU (1) | RU2717558C2 (es) |
| SG (1) | SG11201702628XA (es) |
| UA (1) | UA122672C2 (es) |
| WO (1) | WO2016050358A1 (es) |
| ZA (1) | ZA201703007B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170062518A (ko) | 2014-10-01 | 2017-06-07 | 메르크 파텐트 게엠베하 | 보론산 유도체 |
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| CA2963205A1 (en) | 2014-10-01 | 2016-04-07 | Merck Patent Gmbh | Boronic acid derivatives |
| WO2016050355A1 (en) | 2014-10-01 | 2016-04-07 | Merck Patent Gmbh | Boronic acid derivatives |
| KR102534947B1 (ko) | 2017-01-18 | 2023-05-23 | 프린시피아 바이오파마, 인코퍼레이티드 | 면역프로테아좀 억제제 |
| JP7189203B2 (ja) * | 2017-08-24 | 2022-12-13 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | ボロン酸誘導体 |
| TW201912624A (zh) * | 2017-08-29 | 2019-04-01 | 大陸商浙江海正藥業股份有限公司 | (E)-α,β-不飽和醯胺化合物及其製備方法和用途 |
| US10807951B2 (en) * | 2017-10-13 | 2020-10-20 | The Regents Of The University Of California | mTORC1 modulators |
| AU2018369787B2 (en) * | 2017-11-16 | 2023-04-20 | Principia Biopharma Inc. | Immunoproteasome inhibitors |
| AU2018367515B2 (en) | 2017-11-16 | 2023-04-27 | Principia Biopharma Inc. | Immunoproteasome inhibitors |
| BR112021001359A2 (pt) * | 2018-07-26 | 2021-04-20 | Merck Patent Gmbh | derivados de ácido borônico |
| CN113135943A (zh) * | 2020-01-19 | 2021-07-20 | 首药控股(北京)有限公司 | 硼酸衍生物 |
| CN113135944A (zh) * | 2020-01-19 | 2021-07-20 | 首药控股(北京)有限公司 | 硼酸衍生物 |
| WO2023006863A1 (en) | 2021-07-29 | 2023-02-02 | Merck Patent Gmbh | Novel crystalline forms of [(1r)-2-(1-benzofuran-3-yl)-1-{[(1s,2r,4r)-7- oxabicyclo[2.2.1]heptan-2-yl]formamido}ethyl]boronic acid, adducts thereof, and processes to obtain |
| US20240425529A1 (en) * | 2021-10-14 | 2024-12-26 | Shouyao Holdings (beijing) Co., Ltd. | Boric acid derivative |
| WO2023232830A1 (en) | 2022-06-02 | 2023-12-07 | Merck Patent Gmbh | Boronic acid adducts |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5658885A (en) * | 1993-04-27 | 1997-08-19 | The Dupont Merck Pharmaceutical Company | Amidino and guanidino substituted boronic acid inhibitors of trypsin-like enzymes |
| US5462964A (en) * | 1993-10-20 | 1995-10-31 | The Du Pont Merck Pharmaceutical Company | Dipeptide boronic acid inhibitors of trypsin-like enzymes |
| IL111175A0 (en) * | 1993-10-07 | 1994-12-29 | Du Pont Merck Pharma | Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them |
| AU5788800A (en) * | 1999-07-07 | 2001-01-22 | Du Pont Pharmaceuticals Company | Peptide boronic acid inhibitors of hepatitis c virus protease |
| CA2536010A1 (en) * | 2002-09-09 | 2004-03-18 | Trigen Limited | Boronic acid salts useful in parenteral formulations for selective thrombin inhibition |
| UA88771C2 (ru) * | 2003-08-14 | 2009-11-25 | Сефалон, Инк. | Ингибиторы протеасомы и способ их применения (варианты) |
| US7576206B2 (en) * | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| AR075090A1 (es) * | 2008-09-29 | 2011-03-09 | Millennium Pharm Inc | Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden. |
| US9040703B2 (en) * | 2010-04-22 | 2015-05-26 | Mars, Incorporated | Inhibitors of arginase and their therapeutic applications |
| KR20140114391A (ko) | 2011-12-22 | 2014-09-26 | 아레스 트레이딩 에스.에이. | 알파-아미노 보론산 유도체, 선택적 면역프로테아좀 저해인자 |
| ES2893251T3 (es) | 2014-01-31 | 2022-02-08 | Bristol Myers Squibb Co | Macrociclos con grupos P2 heterocíclicos como inhibidores del factor XIa |
| KR102478309B1 (ko) | 2014-10-01 | 2022-12-15 | 얀센 파마슈티칼즈, 인코포레이티드 | 뎅기 바이러스 복제 억제제로서의 １치환 또는 ２치환 인돌 |
| US9944598B2 (en) | 2014-10-01 | 2018-04-17 | Janssen Pharmaceuticals, Inc. | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors |
| KR20170062518A (ko) | 2014-10-01 | 2017-06-07 | 메르크 파텐트 게엠베하 | 보론산 유도체 |
| WO2016050355A1 (en) | 2014-10-01 | 2016-04-07 | Merck Patent Gmbh | Boronic acid derivatives |
| CA2963205A1 (en) | 2014-10-01 | 2016-04-07 | Merck Patent Gmbh | Boronic acid derivatives |
| NO2721243T3 (es) | 2014-10-01 | 2018-10-20 |
-
2015
- 2015-10-01 WO PCT/EP2015/001973 patent/WO2016050358A1/en not_active Ceased
- 2015-10-01 MY MYPI2017701058A patent/MY186911A/en unknown
- 2015-10-01 CN CN201580053501.9A patent/CN107001391B/zh active Active
- 2015-10-01 US US15/516,427 patent/US10669289B2/en active Active
- 2015-10-01 DK DK15778613.8T patent/DK3201206T3/da active
- 2015-10-01 BR BR112017006622-0A patent/BR112017006622A2/pt not_active Application Discontinuation
- 2015-10-01 KR KR1020177011562A patent/KR102457840B1/ko active Active
- 2015-10-01 RU RU2017115192A patent/RU2717558C2/ru active
- 2015-10-01 EP EP15778613.8A patent/EP3201206B1/en active Active
- 2015-10-01 SG SG11201702628XA patent/SG11201702628XA/en unknown
- 2015-10-01 UA UAA201704168A patent/UA122672C2/uk unknown
- 2015-10-01 ES ES15778613T patent/ES2761774T3/es active Active
- 2015-10-01 JP JP2017518070A patent/JP6662865B2/ja active Active
- 2015-10-01 MX MX2017003999A patent/MX372823B/es active IP Right Grant
- 2015-10-01 AU AU2015327345A patent/AU2015327345B9/en active Active
- 2015-10-01 NZ NZ730981A patent/NZ730981A/en unknown
- 2015-10-01 CA CA2963203A patent/CA2963203A1/en active Pending
-
2017
- 2017-02-16 PH PH12017500293A patent/PH12017500293A1/en unknown
- 2017-03-21 IL IL251302A patent/IL251302B/en active IP Right Grant
- 2017-03-31 CL CL2017000792A patent/CL2017000792A1/es unknown
- 2017-04-28 ZA ZA2017/03007A patent/ZA201703007B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2963203A1 (en) | 2016-04-07 |
| RU2017115192A3 (es) | 2019-03-26 |
| AU2015327345B2 (en) | 2019-12-05 |
| US10669289B2 (en) | 2020-06-02 |
| IL251302B (en) | 2020-03-31 |
| AU2015327345B9 (en) | 2020-06-18 |
| RU2717558C2 (ru) | 2020-03-24 |
| SG11201702628XA (en) | 2017-04-27 |
| DK3201206T3 (da) | 2019-12-16 |
| CN107001391A (zh) | 2017-08-01 |
| BR112017006622A2 (pt) | 2018-07-03 |
| AU2015327345A1 (en) | 2017-05-18 |
| PH12017500293A1 (en) | 2017-06-28 |
| UA122672C2 (uk) | 2020-12-28 |
| KR20170067802A (ko) | 2017-06-16 |
| JP6662865B2 (ja) | 2020-03-11 |
| IL251302A0 (en) | 2017-05-29 |
| ES2761774T3 (es) | 2020-05-21 |
| US20180179232A1 (en) | 2018-06-28 |
| JP2017531646A (ja) | 2017-10-26 |
| MX372823B (es) | 2020-07-03 |
| ZA201703007B (en) | 2022-05-25 |
| MY186911A (en) | 2021-08-26 |
| RU2017115192A (ru) | 2018-11-06 |
| EP3201206A1 (en) | 2017-08-09 |
| KR102457840B1 (ko) | 2022-10-21 |
| CL2017000792A1 (es) | 2017-11-10 |
| CN107001391B (zh) | 2020-11-27 |
| WO2016050358A1 (en) | 2016-04-07 |
| NZ730981A (en) | 2024-01-26 |
| EP3201206B1 (en) | 2019-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017003999A (es) | Derivados de acido boronico. | |
| MX2017004037A (es) | Derivados de acido boronico. | |
| MX2017004043A (es) | Derivados de acido boronico. | |
| MX2017004046A (es) | Derivados de acido boronico. | |
| EA201692203A1 (ru) | Соединения, ингибирующие tank-связывающую киназу | |
| PH12017500509A1 (en) | Benzyl substituted indazoles as bub1 inhibitors | |
| GEAP201814288A (en) | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors | |
| EA201691916A1 (ru) | Биарильные ингибиторы киназы | |
| EA201891024A1 (ru) | Соединения-ингибиторы tank-связывающей киназы | |
| EA201792205A1 (ru) | Гетероциклические соединения как ингибиторы lsd1 | |
| CL2016001082A1 (es) | Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa | |
| UY36175A (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
| CL2016001790A1 (es) | Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2. | |
| CL2015002932A1 (es) | Inhibidores de proteína quinasa | |
| EA201891344A1 (ru) | Новые агонисты рецептора апелина и способы применения | |
| UY35500A (es) | Indazoles sustituidos con heteroarilo | |
| EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
| CL2018000649A1 (es) | Nuevos compuestos bicíclicos como inhibidores duales de atx / ca | |
| AR095075A1 (es) | Acoplamiento electroquímico de anilinas | |
| EA201691982A1 (ru) | 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов | |
| CL2016003074A1 (es) | Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer. | |
| MX2017001352A (es) | Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2). | |
| EA201792096A2 (ru) | РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА | |
| EA201691983A1 (ru) | Пиридин-2-амиды, пригодные в качестве агонистов cb2 | |
| EA201690244A1 (ru) | Ингибиторы киназ на основе простых ариловых эфиров |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |